Promethera Biosciences to present at the 2016 Cell & Gene Meeting on the Mesa

Mont-Saint-Guibert, Belgium, September 29, 2016 – Promethera Biosciences SA, a Belgian biotechnology company with U.S. operations developing cell therapies treating a broad range of liver diseases with high unmet medical needs, today announces that Dr. Torsten Hombeck, Chief Commercial & Strategy Officer, Promethera, will present at the Cell & Gene Meeting on the Mesa. The event will be on October 5-7 in La Jolla, California, US.

The presentation will be held at 4.30pm PST on October 6, 2016. It will include an update on Promethera’s research and development pipeline as well as the strategy and corporate goals following Promethera’s recent acquisition of key assets of Cytonet, the international cellular therapy company involving primary human hepatocytes. This transaction has made Promethera the world’s leading and most
advanced cell therapy and regenerative medicine company targeting a broad range of liver diseases.

“Promethera continues its strategy to build the most advanced company in the field of stem cell therapies for the treatment of inborn liver metabolic diseases and acquired liver diseases,” said Dr. Torsten Hombeck, Chief Commercial & Strategy Officer, Promethera Biosciences, “It is important for Promethera to share the current advances and experiences on new cell based treatment approaches to these pathologies to the benefit of the entire cell therapy community. The Partnering Forum at The Cell & Gene Meeting on the Mesa provides an excellent opportunity to present both the latest Promethera corporate and scientific developments.”


Organized by the Alliance for Regenerative Medicine (ARM) and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives from the cell and gene therapy and the scientific communities to discuss the most pressing issues facing the sector.

A live video webcast of Torsten Hombeck’s presentation will be available at: and will also be published on ARM’s website shortly after the event.